IRCT20200105046010N4尚未招募未知
In- Vivo Bioequivalence study of Empagliflozin, Linagliptin tablet 25,5mg ABIDI (Glorenta 25, 5mg) with brand drugs (Glyxambi 25, 5mg Boehringer Ingelheim, Gremany) in Iranian healthy volunteers.
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health(liver, heart, kidney)
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
尚未招募
Unknown
Bioequivalence Study of Empagliflozin/Linagliptin 25/5 mg Kharazmi Pharma CoThis study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N97Kharazmi Pharmaceutical Co24
招募中
不适用
In-vivo Bioequivalence Test of Empagliflozin tablets with brand drug (JARDIANCE® 25 mg, Boehringer Ingelheim , Germany)Bio equivalence test.IRCT20200105046010N49Pars Darou Pharm. Co.24
招募中
不适用
In-vivo Bioequivalence Test of Empagliflozin-Metformin tablets with brand drug (Synjardy® 25/1000 mg, Boehringer Ingelheim, Germany)Bio equivalence test.IRCT20200105046010N60Pars Darou Pharmaceutical Company24
尚未招募
不适用
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditionsIRCT20180620040164N13ACtover Pharmaceutical Co26
招募中
不适用
Bioequivalence study of Empagliflozin 25 mg tablet in 24 healthy male under fasting conditionsBioequivalence investigation of the generic Actoverco. Empagliflozin 25 mg tablet with brand Jardiance 25 mg tablet Boehringer..IRCT20180620040164N19Actover Pharmaceutical Co.24